Kétoprofène Ranbaxy

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Kétoprofène Ranbaxy

Property Description
Active Ingredient Ketoprofen
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Subgroup Arylpropionic Acid Derivative
Forms Available Capsule, Tablet, Topical Gel, Solution for Injection
Origin Synthetic (Chemically Synthesized)

What Type of Medicine is Kétoprofène Ranbaxy?

Kétoprofène Ranbaxy is a medicinal preparation whose essential active ingredient is Ketoprofen. This medication is classified pharmacologically as a Non-Steroidal Anti-Inflammatory Drug (NSAID), belonging specifically to the arylpropionic acid derivative group. Ketoprofen is a synthetic compound, chemically synthesized and structurally related to other common NSAIDs like ibuprofen. The drug is clinically recognized for its potency among the propionic acid derivatives. The identity of this single-product drug is strictly defined by the action and composition of the Ketoprofen compound, affirming that the medicine is designed to target pain and inflammation in the adult population, often requiring a prescription (Rx) for most oral forms.


Forms, Administration Routes, and Composition

The Ketoprofen compound is made available in several distinct dosage forms to accommodate various patient needs. These presentations include oral preparations (capsule and tablet), a topical gel for application to the skin, and a solution for injection for parenteral administration. Each form facilitates a different route of administration, such as systemic treatment via the oral route or localized relief via the topical route. The core composition consists of the active Ketoprofen compound combined with various pharmacologically inert excipients, bases, or vehicles, which ensure stability and proper delivery to the body.


What is the General Purpose of Kétoprofène Ranbaxy?

The general purpose of the medication is to provide effective symptomatic relief from conditions characterized by pain, swelling, and fever, such as managing discomfort associated with a flare-up of rheumatoid arthritis or a musculoskeletal strain. The action of Ketoprofen involves the interruption of the body's natural inflammatory cascade. This class of drug works by inhibiting cyclooxygenase (COX) activity. This essential action reduces the production of prostaglandins, which are the key chemical mediators responsible for generating pain signals and triggering the physical responses of inflammation and elevated body temperature. Consequently, Kétoprofène Ranbaxy delivers a three-fold therapeutic benefit, functioning powerfully as an anti-inflammatory agent, an analgesic (pain reliever), and an antipyretic (fever reducer).

Regulatory References

  1. National Institutes of Health (NIH)
Advertisements

What side effects are possible with Kétoprofène Ranbaxy?

Possible Side Effects and Safety Information

Kétoprofène Ranbaxy, like other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), carries an increased risk of serious cardiovascular thrombotic events (including myocardial infarction and stroke) and serious gastrointestinal adverse events (including bleeding, ulceration, and perforation), which can be fatal. This risk may increase with higher doses and longer durations of treatment.

Adverse Reaction Classification

Frequency Common Adverse Reactions (Selected) Serious Reactions (Regulatory Focus)
Common (1% to 10%) Dyspepsia, nausea, abdominal pain, headache, dizziness, somnolence. N/A
Uncommon (0.1% to 1%) Diarrhea, constipation, flatulence, rash, fatigue, peripheral edema. N/A
Rare/Frequency Not Known Gastrointestinal bleeding/ulceration, severe skin reactions (e.g., Stevens-Johnson Syndrome), anaphylaxis (allergic shock), renal failure, hypertension, severe hepatic disorders. Cardiovascular thrombotic events (MI/stroke), GI bleeding and perforation, anaphylactic shock, severe dermatoses.

Safety Considerations

System-Organ Classes Involved: Adverse reactions involve the gastrointestinal system, nervous system, immune system, skin and subcutaneous tissue, cardiovascular system, and renal/hepatic systems.

Population-Specific Warnings: Elderly patients, or those with low body weight, are at a higher risk for serious gastrointestinal complications and require careful monitoring of renal, hepatic, and cardiac function. The medication is contraindicated from the beginning of the sixth month of pregnancy (after 24 weeks of amenorrhea) due to the risk of fetotoxicity, including cardiopulmonary and renal dysfunction in the fetus.

Restrictions/Limitations: The product is absolutely contraindicated in cases of active peptic ulcer or bleeding, severe heart failure, severe liver insufficiency, severe renal insufficiency, and history of allergy to ketoprofen, aspirin, or other NSAIDs. Treatment must be immediately discontinued if signs of serious skin reactions, gastrointestinal bleeding, or ulceration occur.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose with Kétoprofène Ranbaxy, or accidental intoxication, requires immediate and urgent medical attention. There is no specific antidote; management relies on supportive and symptomatic care in a medical setting.

Signs of overdose are primarily divided into two major systems:

  • Gastrointestinal (GI) Symptoms: Nausea, vomiting (which may include blood), severe abdominal pain, and potential for gastrointestinal bleeding, ulceration, or perforation. In severe cases, these events can be life-threatening.
  • Central Nervous System (CNS) Symptoms: Drowsiness, dizziness, headache, confusion, agitation, and, in severe intoxication, seizures or coma. Respiratory depression (slow, shallow breathing) and signs of acute renal (kidney) or cardiovascular dysfunction, such as hypotension, have also been officially documented.

In the event of suspected overdose or accidental ingestion of an excessive amount, immediately stop the medication and consult a physician or emergency medical services (e.g., call the local emergency number or a poison control center). Treatment may involve gastrointestinal decontamination procedures if the ingestion is recent (e.g., within four hours), along with continuous monitoring of vital signs and supportive measures to address specific symptoms and protect organ function. Due to the potential for serious damage to the kidneys, stomach, and central nervous system, rapid medical intervention is essential.

Advertisements

Therapeutic Uses of Kétoprofène Ranbaxy

What Kétoprofène Ranbaxy Treats: Main Uses and Benefits

Kétoprofène Ranbaxy is relevant in contexts marked by increased discomfort or tension, and is commonly used to help with pain, inflammation, and fever. It is applied across domains where additional symptomatic support is needed in conditions associated with acute or disruptive episodes.

It is commonly used to help manage symptoms related to physical discomfort, such as muscle aches, menstrual cramps, dental pain, and to ease swelling associated with joint stiffness. It provides supportive relief in situations where patients experience symptoms that interfere with daily functioning. The medication is applied across domains where additional symptomatic support is needed.

The medication contributes to easing the overall symptom load. It is often used during phases when symptoms become more noticeable and supportive relief is needed. This supports general well-being during symptomatic phases and helps improve day-to-day comfort.


Quick Fact: Symptomatic Support for Pain and Inflammation


Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Kétoprofène Ranbaxy — Official Regulatory Information

Kétoprofène Ranbaxy (ketoprofen) is a non-steroidal anti-inflammatory drug (NSAID) whose use is strictly defined by regulatory guidelines. The medicine is contraindicated and must not be used by specific populations due to the risk of serious adverse events.

Contraindicated Populations and Conditions

Category Restriction Status
Allergy Contraindicated in patients with hypersensitivity to ketoprofen, aspirin, or other NSAIDs (including history of asthma, rhinitis, or urticaria).
Pregnancy Contraindicated during the third trimester of pregnancy.
Gastrointestinal Contraindicated with active gastric or duodenal ulcer, chronic dyspepsia, gastritis, or any history of GI bleeding, ulceration, or perforation.
Cardiovascular Contraindicated with severe cardiac insufficiency and for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Blood Disorders Contraindicated in patients with leukocytopenia or thrombocytopenia.

Populations Requiring Special Consideration

  • Pediatric Use: Safety and efficacy have not been established in the pediatric population (typically under 18 years old).
  • Elderly Patients: Should be used with caution at the lowest effective dose due to increased risk of serious GI events and potential age-related renal impairment.
  • Renal/Hepatic Impairment: Requires close monitoring and potential dose adjustment for patients with chronic liver disease (especially with low serum albumin) or impaired renal function.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Kétoprofène, as a non-steroidal anti-inflammatory drug (NSAID), has a number of documented interactions that increase the risk of adverse events, primarily those affecting the gastrointestinal tract and renal function. Combinations should be carefully assessed due to increased potential for toxicity.

Interacting Product Category Specific Examples and Interaction Risk
Other NSAIDs (including Aspirin at anti-inflammatory doses) Increased risk of gastrointestinal (GI) bleeding and ulceration. This combination is generally contraindicated by official labeling.
Anticoagulants (e.g., Warfarin, Heparin) Potentiation of the anticoagulant effect, leading to a significantly increased risk of major bleeding and hemorrhage. Close monitoring of blood clotting parameters (e.g., INR) is required.
Diuretics / ACE-Inhibitors / ARBs (e.g., Furosemide, Lisinopril) Reduced effectiveness of the antihypertensive or diuretic drug. Risk of developing or worsening renal impairment/failure due to diminished renal blood flow.
Lithium NSAIDs can increase plasma lithium levels, potentially leading to toxicity, requiring careful monitoring.
Ciclosporin / Methotrexate Increased risk of nephrotoxicity (kidney damage) with ciclosporin and increased risk of methotrexate toxicity due to reduced clearance, necessitating close monitoring.

For the topical gel formulation, treatment carries a risk of photosensitivity. Co-application with cosmetic or care products containing the chemical sunscreen ingredient octocrylene may lead to skin reactions, even without exposure to sunlight, and necessitates immediate cessation of treatment if a reaction occurs. Furthermore, exposure to sun or UV light must be strictly avoided during treatment with the topical product and for two weeks after discontinuation.

Advertisements

Mechanism of Action

How Kétoprofène Ranbaxy Works

The action of Kétoprofène Ranbaxy is rooted in its active ingredient, Ketoprofen, which functions by modulating fundamental enzymatic processes responsible for producing physiological mediators. Its mechanism involves non-selective inhibition across three core domains, resulting in defined physiological consequences.


Enzyme Inhibition of Prostaglandin Synthesis

The primary mechanism involves the non-selective, reversible inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. By blocking the COX enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins, which are chemical messengers that mediate nociceptive and inflammatory processes.


Modulating Pain Signal Sensitization

The molecular blockade results in a reduction of prostaglandins that act to sensitize peripheral pain receptors (nociceptors). The mechanism thereby modulates the signal transmission capability of nerve endings by reducing sensitization, which constitutes the physiological basis for pain modulation.


️ Central Control of Thermoregulation

A specific component of the mechanism involves the inhibition of Prostaglandin E2 ( PGE2) synthesis within the central nervous system, particularly in the hypothalamus. This central action modulates the elevated thermoregulatory set point, initiating physiological adjustments consistent with fever reduction.

Advertisements

Dosage and Administration Information

Kétoprofène Ranbaxy is administered via two primary routes: oral for systemic action (capsules, tablets) and topical for localized application (gels). The required administration method is determined by the specific preparation chosen.

For Immediate-Release (IR) oral forms, the standard adult regimen is typically 50 mg four times daily or 75 mg three times daily for consistent coverage, with a maximum daily dose of 300 mg. For periodic use, dosing is generally 25 mg to 50 mg every 6 to 8 hours as needed. Extended-Release (ER) capsules, however, are administered once daily at 200 mg and are not intended for managing acute discomfort.

Oral preparations must be taken with a full glass of water and may be combined with food, milk, or antacids to aid administration. If a dose is missed, guidance advises taking it as soon as remembered, unless it is close to the next scheduled dose, in which case the missed dose should be skipped; doses must not be doubled.

Standard instructions mandate that lower initial doses must be considered for older adults and patients with known severe renal or hepatic impairment due to altered drug clearance. Topical applications are applied to the affected area, typically two to four times daily, and require gentle and prolonged massage into the skin.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kétoprofène Ranbaxy

The available research for Kétoprofène Ranbaxy (Ketoprofen) has explored outcomes related to symptoms associated with pain, inflammation, and fever. The evidence primarily stems from controlled clinical trials and comprehensive reviews that explore short-term and intermediate symptom patterns in adult populations. Findings describe group patterns observed under specific research conditions.


Research Evidence for Managing Chronic Pain and Inflammation

The evidence base for long-term conditions characterized by fluctuating or episodic manifestations like rheumatoid arthritis and osteoarthritis primarily relies on Randomized Controlled Trials (RCTs) and systematic reviews. Research examined how symptoms were measured in adult populations over defined time intervals. Studies monitored patient-reported outcomes describing perceived discomfort, such as changes in pain scores and measurements of joint function and stiffness. While research highlights changes measured during the study period, there is limited information for long-term outcomes that extend beyond three months. Furthermore, research involving continuous systemic use highlights the limited duration of available long-term safety data.


Studies on Acute Pain Relief (Short-Term Use)

For conditions associated with acute or disruptive episodes such as post-operative pain and primary dysmenorrhea (menstrual cramps), the evidence is derived mainly from short-term, placebo-controlled RCTs. Research explored outcomes describing episodic or acute changes, such as the time taken to report initial changes and the overall length of time symptoms were monitored. Since the trials for acute symptom patterns are usually limited to a short follow-up duration, the data are not designed to provide insight into long-term functional recovery or how symptoms were measured in the weeks or months following the initial acute event.


Research Gaps and Remaining Uncertainties

The current evidence base provides insight into short-term changes but there is limited information for long-term outcomes for most conditions, particularly regarding long-term functional status over several years. Data for certain groups remain insufficient, especially for children and some highly specific comorbidity-defined subgroups. Research was observed in a variety of adult populations; however, specific structural evidence for all patient groups is not equally established, and results apply only to the populations studied under the specific conditions of the trial.

Key Studies & References

  1. Ketoprofen - LiverTox - NCBI Bookshelf (NIH - Review of use in chronic arthritis and systemic risk profile)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Kétoprofène Ranbaxy (FAQ)

Q: Is Kétoprofène Ranbaxy available over the counter?

According to official product information, the oral forms of ketoprofen, including Kétoprofène Ranbaxy, are generally classified as prescription-only medication (Rx) in most major regulatory regions.


Q: What age group is Kétoprofène Ranbaxy typically recommended for?

The medication is officially indicated for use in the adult population. Safety and efficacy have generally not been established for the pediatric population, which typically includes those under 18 years old.


Q: Are there different strengths or formulations of Kétoprofène Ranbaxy?

Yes. The active ingredient, ketoprofen, is available in multiple formulations to suit different needs, including immediate-release capsules (such as 50 mg and 75 mg), extended-release capsules (such as 200 mg), and a topical gel for application to the skin.


Q: What kind of pain is Kétoprofène Ranbaxy best for?

Official indications describe the medication's use for the symptomatic management of pain and inflammation associated with a range of conditions. This includes chronic pain from conditions like rheumatoid arthritis and osteoarthritis, as well as acute pain from conditions like primary dysmenorrhea (menstrual pain) and general pain.


Q: How quickly does Kétoprofène Ranbaxy usually start to work?

The active ingredient is absorbed relatively quickly. Regulatory pharmacokinetic data show that peak levels in the blood typically occur within 0.5 to 2 hours after taking an immediate-release capsule.


Q: How long does the effect of Kétoprofène Ranbaxy usually last?

The corresponding dosing interval for immediate-release forms is typically structured to provide relief over a period of 6 to 8 hours, which reflects the generally expected duration of the medicinal effect.


Q: What is the half-life of Kétoprofène Ranbaxy?

The elimination half-life of the active ingredient, ketoprofen, is reported in regulatory documents to be approximately 2 hours following the administration of immediate-release capsules. The half-life describes the time it takes for half of the drug to be eliminated from the body.


Q: Is there a maximum number of days I can take Kétoprofène Ranbaxy?

Official guidance emphasizes using the lowest effective dose for the shortest duration necessary. This is a core safety principle for this class of drug, as potential risks may increase with the duration of use.


Q: Is there a risk of dependency or addiction with Kétoprofène Ranbaxy?

No. Kétoprofène Ranbaxy is a Non-Steroidal Anti-Inflammatory Drug (NSAID). This medication is not classified as an opioid and is not listed as a controlled substance with a risk of dependency or addiction.


Q: Does taking Kétoprofène Ranbaxy cause drowsiness or sleepiness?

Yes, this is possible. Official labeling lists somnolence (drowsiness or sleepiness) as a common adverse reaction, meaning it occurs in 1% to 10% of patients in clinical trials.


Q: Is it common to have dizziness after taking Kétoprofène Ranbaxy?

Yes, dizziness is listed in regulatory information as a common adverse reaction, typically occurring in 1% to 10% of patients.


Q: Does Kétoprofène Ranbaxy cause water retention or swelling?

Official labeling lists peripheral edema (swelling or water retention) as an uncommon adverse reaction. Regulatory warnings mention that symptoms such as fluid retention, shortness of breath, or unexplained weight gain may occur.


Q: Is it normal to feel a burning sensation in my chest after taking this drug?

A common adverse reaction to this class of drug is dyspepsia (indigestion), which may be described by patients as heartburn or a burning sensation in the chest or stomach area.


Q: What are the common signs of an allergic reaction to Kétoprofène Ranbaxy?

Signs of a less severe hypersensitivity reaction can include a rash, hives, or itching. More serious reactions, such as swelling of the face, throat, or tongue, or difficulty breathing, are noted as symptoms requiring prompt attention from a healthcare professional.


Q: What is the connection between Kétoprofène Ranbaxy and kidney function?

Official labeling indicates that ketoprofen can affect renal (kidney) function, especially in patients with existing impairment. Close monitoring and potential dose adjustment are required due to the drug's effect on altered clearance in these populations.


Q: What happens if I take Kétoprofène Ranbaxy on an empty stomach?

Official guidance suggests taking the medication with a full glass of water, and potentially with food, milk, or an antacid to help with administration. Taking the medicine without food may lead to faster absorption, but this could potentially increase the risk of gastrointestinal discomfort.


Q: Is there a food or drink that stops Kétoprofène Ranbaxy from working well?

Regulatory information indicates that while taking the medication with food may slow the rate at which the active ingredient is absorbed into the body, the total amount of medication absorbed remains consistent, meaning it does not stop it from working.


Q: Can Kétoprofène Ranbaxy interact with alcohol?

Yes. Alcohol use, especially when combined with prolonged therapy, is described in warnings as significantly increasing the risk of serious gastrointestinal bleeding associated with this class of drug.


Q: Does Kétoprofène Ranbaxy interact with herbal supplements?

Official warnings advise informing a healthcare provider about the use of all medications, including vitamins and herbal supplements. This is because some herbs may increase the risk of bleeding when taken alongside this drug.


Q: Can taking Kétoprofène Ranbaxy cause sun sensitivity?

Increased sensitivity of the skin to sunlight (photosensitivity) has been noted as a potential side effect of the oral form. The topical gel formulation specifically warns to strictly avoid sun exposure during treatment and for two weeks after discontinuation.


Q: What studies have been done on the long-term use of Kétoprofène Ranbaxy?

Research evidence includes Randomized Controlled Trials (RCTs) and systematic reviews that focus on monitoring patient-reported outcomes for chronic conditions like arthritis. These studies typically track changes in pain scores and measurements of joint function and stiffness over defined time periods.


Q: Can Kétoprofène Ranbaxy be crushed or split?

Official instructions describe taking the capsules whole. Extended-release capsules, in particular, are designed to release medication slowly over time and regulatory instructions state they should not be crushed, split, or chewed, as this can affect the way the medication works.


Q: Can I use Kétoprofène Ranbaxy for dental pain?

Official regulatory indications specify that this medication is used for the management of pain and inflammation, covering a range of acute conditions like general pain and musculoskeletal strains.


Q: Is it okay to take Kétoprofène Ranbaxy before or after minor surgery?

Official labeling contraindicates use in the setting of Coronary Artery Bypass Graft (CABG) surgery due to cardiovascular risks. This class of medication carries a general risk of bleeding, which is a key factor when considering use around any surgical procedure.


Q: Can women who are planning pregnancy use Kétoprofène Ranbaxy?

Official regulatory warnings note that the use of this class of medication is sometimes associated with a reversible impairment of female fertility. Women who are planning to become pregnant may want to consult a healthcare professional regarding the use of this class of medication.


Q: Are there official warnings about taking Kétoprofène Ranbaxy while breastfeeding?

Regulatory-cited information notes that the active ingredient passes into breastmilk at low levels. Reports of potential adverse gastrointestinal and renal side effects in infants have led to the suggestion that other agents may be preferred while nursing.


Q: Is it safe to drive after taking Kétoprofène Ranbaxy?

Because this medication may cause side effects such as dizziness, drowsiness (somnolence), or blurred vision, official information suggests that driving or operating machinery should be avoided until it is known that the user can perform such activities safely.


Q: What should I do if I feel dizzy or lightheaded while taking Kétoprofène Ranbaxy?

Regulatory documents suggest contacting a healthcare provider if common side effects like dizziness last or become severe, or if new, unusual, or worsening symptoms occur.

Advertisements

How should Kétoprofène Ranbaxy be stored and disposed of?

Storage and Disposal of Kétoprofène Ranbaxy

Official regulatory guidelines require the strict adherence to specific conditions to maintain the stability and safety of Kétoprofène (Ketoprofen) oral forms.

Storage Requirements

  • Temperature and Environment: The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Storage is prohibited in environments exposed to excess heat, moisture, or freezing temperatures.
  • Protection: The product must be stored away from direct light and kept in its original container, which must be tightly closed.
  • Child Safety: Kétoprofène Ranbaxy must be kept strictly out of the sight and reach of children, utilizing a child-resistant closure as required by the label.

Disposal Instructions

Unused or expired medication should not be kept. Regulatory instructions advise users to consult a healthcare professional or utilize an approved drug take-back program at a local pharmacy for proper and safe disposal, preventing environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kétoprofène Ranbaxy found in:

A-Z Index: